P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias

Haematologica

Volumn 83, Issue 4, 1998, Pages 290-297

  Damiani, Daniela ^a   Michieli, Mariagrazia ^a   Ermacora, Anna ^a   Candoni, Anna ^a   Raspadori, Donatella ^b   Geromin, Antonella ^a   Stocchi, Raffaella ^a   Grimaz, Stefania ^a   Masolini, Paola ^a   Michelutti, Angela ^a   Scheper, Rik J ^c   Baccarani, Michele ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Lung resistance related protein; P glycoprotein; Prognosis; Secondary leukemias

Indexed keywords

CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; VALSPODAR;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ACCUMULATION; FLOW CYTOMETRY; FLUORESCENCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD34; BONE MARROW CELLS; CELL LINE; DAUNORUBICIN; HUMANS; INTRACELLULAR FLUID; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; LEUKOCYTES; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; P-GLYCOPROTEIN; PROGNOSIS; TREATMENT OUTCOME; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 18344411220     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Champlin F, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69:1551-61.
2. Gajewski JO, Ho WG, Nimer SD, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989; 7:1637-45.
3. th AML trial. BrJ Haematol 1989; 72:45-53.
4. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4:1748-57.
5. Martiat P, Ferrant A, Michaux JL, Sokal G. Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hematol Oncol 1988; 6:299-305.
6. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79:473-6.
7. Ino T, Miyazaki H, Isogai M, et al. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia 1994; 8:1492-9.
8. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993; 7:825-31.
9. Michieli M, Damiani D, Geromin A, et al. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992; 48:87-92.
10. Wood P, Burgess R, MacGregor A, Yin JAL. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotheapy and survival. Br J Haematol 1994; 87:509-14.
11. Zöchbauer S, Gsur A, Brunner R, Kyrie PA, Lechner K, Pirker R. P-glycoprotein expression as unfavourable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8:974-7.
12. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990; 21:34-48.
13. Gottesman MM, Pastan I. Resistance to multiple chemotherapeutic agents in human cancer cells. TIPS 1989; 91:54-8.
14. Hait WN, Aftab DT. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol 1992; 43:103-7.
15. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735-9.
16. Damiani D, Michieli M, Michelutti A, Fanin R, Russo D, Baccarani M. P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia. Leuk Lymphoma 1995; 17:289-94.
17. Drach D, Zhao S, Drach J, et al. Subpopulation of normal peripheral blood and bone marrow cell express a functional multidrug resistant phenotype. Blood 1992; 80:2729-34.
18. Pileri SA, Sabattini E, Falini B, et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991; 19:131-40.
19. Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res 1988; 48:1926-9.
20. Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-8.
21. Schinker AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77:491-502.
22. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural products drugs. Cancer Res 1994; 54:357-61.
23. Izquierdo MA, Scheffer GL, Flens MJ. Schroeijers AB, Van der Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. EurJ Cancer 1996; 32A: 979-84.
24. Michieli M, Damiani D, Michelutti A, et al. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives. Haematologica 1994; 79:119-26.
25. Kuiper CM, Boxtermann HJ, Baas F, et al. Drug transport variant P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1990; 1:35-41.
26. Damiani D, Michieli M, Michelutti A, et al. Expression of multidrug resistance gene (mdr-1) in human normal leukocytes. Haematologica 1993; 78:12-7.
27. Michieli M, Damiani D, Michelutti A, et al. Screening for multidrug resistance in leukemia: cell reactivity to MRK-16 correlates with anthracycline retention and sensitivity of leukemic cells. Leuk Lymphoma 1996; 18:179-94.
28. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associted multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56:3010-20.
29. Luk CK, Tannock IF. Flow cytometry analysis of doxorubicin accumulation in cells from human and rodent cell lines. J Natl Cancer Inst 1989; 81:55-9.
30. Guerci A, Merlin JL, Missoum N, et al. Predictive value for treatment outcome in acute leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 85:2147-53.
31. Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 1994; 8:998-1004.
32. Sato H, Preisler H, Day R, et al. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 1990; 75:340-5.
33. Sonnenveld P, van Dongen JJM, Hagemaijer A, et al. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia 1993; 7:963-9.
34. Cumber PM, Jacobs A, Hoy T, et al. Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukemia. Br J Haematol 1990; 76:226-30.
35. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. BrJ Haematol 1997; 96:356-65.
36. Leith CL, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323-9.
37. List AF, Spier CM, Cline A, etal. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991; 78:28-34.
38. Scheffer GL, Wijngaard PLJ, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein. Nature Medicine 1995; 1:578-80.
39. Eijdems EWHM, Borst P, Jongsma APM, et al. Genetic transfer of non P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc Natl Acad Sci USA 1992; 89:3498-502.
40. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87:2464-9.
41. Broxterman HJ, Sonneveld P, Feller N, et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996; 87:4809-16.
42. van den Heuvel-Eibrink MM, van der Holt B, te Boeckhorst PAW, et al. MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukemia. Br J Haematol 1997; 99:76-83.
43. Borg AG, Burgess R, Scheper RJ, Yin JAL. Clinical significance of LRP expression in acute myeloid leukemia (AML). Br J Haematol 1996; 93(suppl. 2):348a.
44. te Boeckhorst PAW, Loewenberg B, Van Kapel J, Nooter K, Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995; 9:1025.
45. Sonneveld P, van Rens GL, de Boevere MJ, Schoester M, Scheper R, Smit E. Molecular and functional analysis of multidrug resistance phenotypes in poor risk AML with -7/7q- karyotype. Blood 1995; 86 (suppl 1):2055a.